相关实验视频

Updated: Jul 11, 2025

Refined Murine Model of Idiopathic Pulmonary Fibrosis

Refined Murine Model of Idiopathic Pulmonary Fibrosis

Published on: June 17, 2025

欧巴林通过激活Sestrin2/PI3K/Akt/mTOR依赖的自道来抑制肺纤维化

Hui Gong¹, Xing Lyu², Yang Liu³

¹Department of Geriatrics, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China; Human Clinical Medical Research Center for Geriatric Syndrome, Changsha, Hunan 410011, China.

|November 2, 2023

概括

欧巴提林是一种亚洲的化合物,通过通过Sestrin2/PI3K/Akt/mTOR通路激活自,有效治疗肺纤维化. 这项研究为异常性肺纤维化 (IPF) 提供了一个新的治疗点.

科学领域:

生物化学生物化学
细胞生物学细胞生物学
药理学药理学是指药理学的学科.

背景情况:

异形性肺纤维化 (IPF) 是一种慢性炎症性肺病,治疗选择有限.
欧巴提林,来自亚洲,在各种组织中显示出抗纤维性潜力.
在IPF中eupatilin的机制尚不清楚.

研究的目的:

研究eupatilin在肺纤维化中的治疗作用和潜在机制.
探索eupatilin在IPF模型中调节纤维细胞激活和自的作用.

主要方法:

利用TGF-β1诱导的肺纤维细胞,IPF患者衍生的细胞,以及白素诱导的肺纤维化小鼠模型.
采用西斑,免疫光,qPCR和电子显微镜来评估纤维化标志物和自.
RNA测序确定了参与eupatilin作用的关键信号通路.

主要成果:

欧巴林降低了纤维化标志物 (Col1A1,纤维素,α-SMA) 和增加了自标志物 (LC3B II/I,自体).
欧巴林抑制PI3K/Akt/mTOR通路,并促进了Sestrin2的表达.
塞斯特林2 knockdown 加剧了纤维化和自功能受损,而eupatilin的作用通过自抑制或Akt激活而逆转.

结论:

欧巴林通过调节Sestrin2/PI3K/Akt/mTOR依赖的自道来改善肺纤维化.
这些发现突出了eupatilin作为IPF的潜在治疗剂.

关键词:

自自是一种自的过程.欧帕提林是什么意思异形性肺纤维化症异形性肺纤维化症在PI3K/Akt/mTOR中使用.这就是Sestrin2的原因.

更多相关视频

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis

Published on: May 9, 2025

A Mouse Model of Pulmonary Fibrosis Induced by Nasal Bleomycin Nebulization

A Mouse Model of Pulmonary Fibrosis Induced by Nasal Bleomycin Nebulization

Published on: January 20, 2023

相关概念视频

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...

PI3K/mTOR/AKT Signaling Pathway

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...

The JAK-STAT Signaling Pathway

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...

Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal

Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal

Erythropoietin-producing hepatocellular carcinoma receptor (Eph) and its ligand, Eph receptor-interacting protein (Ephrin) were first discovered in the human carcinoma cell line, hence the name. Ephrin-Eph interaction guides cells to reach their appropriate location in adult tissues. They also play an essential role in the immune system by helping in immune cell migration, adhesion, and activation. Based on their structure and function, Eph is divided into two classes — EphA and EphB.